基于多胺代谢的药物联合疗法在癌症治疗中的应用  

Application of Drug Combination Therapy Based on Polyamine Metabolism in Cancer Treatment

作　　者：焦宇彤 刘森 JIAO Yu-Tong;LIU Sen(Cooperative Innovation Center of Industrial Fermentation(Ministry of Education&Hubei Province),Hubei University of Technology,Wuhan 430068,Hubei,China;Key Laboratory of Fermentation Engineering(Ministry of Education),Hubei University of Technology,Wuhan 430068,Hubei,China;Hubei WEL-SAFE Biotechnology Co.,Ltd,Ezhou 436006,Hubei,China)

机构地区：[1]湖北工业大学工业发酵省部共建协同创新中心,湖北武汉430068 [2]湖北工业大学发酵工程教育部重点实验室,湖北武汉430068 [3]湖北微生元生物科技有限公司,湖北鄂州436006

出　　处：《中国生物化学与分子生物学报》2024年第11期1539-1549,共11页Chinese Journal of Biochemistry and Molecular Biology

基　　金：国家自然科学基金面上项目(No.31971150);湖北省杰出青年基金项目(No.2019CFA069);工业发酵省部共建协同创新中心开放基金资助。

摘　　要：多胺是一类普遍存在于生物体中的聚阳离子,对生命活动发挥至关重要的作用。在肿瘤中,多胺稳态通常失调。肿瘤的发生和发展过程都需要高水平的多胺,因此,多胺代谢是癌症治疗的合理靶点。经过几十年的发展,研究人员已经发现多胺代谢途径中各个关键酶的靶向调控分子,由于代偿机制、生物利用度低、快速代谢和高毒性,单独靶向多胺代谢途径中某个节点的方法存在局限性。由于协同作用的存在,药物组合使用可以在更低剂量、更低毒性的条件下实现更佳的治疗效果,与单药作用相比更具有优势。本文综述了近年来这种药物联合疗法在癌症治疗中的研究进展。Polyamines are a class of polycations that are ubiquitous in living organisms and play a vital role in physiological activities.In tumors,polyamine homeostasis is often dysregulated,and high levels of polyamine are required for tumor cell growth and tumor progression,rendering the polyamine metabolism pathway a reasonable target for tumors therapy.However,even though researchers have discovered druggable regulators of the polyamine metabolic pathway,due to the compensatory response,low bioavailability,rapid metabolism,and high toxicity,targeting a single regulator has some limitations.Therefore,drug synergism can achieve better therapeutic effects at lower doses and lower toxicity,which is more advantageous than monotherapy.Here we review the advance of this drug combination therapy based on polyamine metabolism in tumors treatment in recent years.

关 键 词：多胺代谢 联合用药 癌症治疗 临床应用 

分 类 号：R730[医药卫生—肿瘤] Q7[医药卫生—临床医学]